Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPCN 1154
- Development stage
- Unknown
- Lead developer
- Lipocine
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
LPCN 1154 is an investigational oral formulation of brexanolone, a bioidentical version of the endogenous neuroactive steroid allopregnanolone. It is being developed for the rapid treatment of postpartum depression (PPD), aiming to provide a convenient, at-home alternative to the current standard of care, which requires intravenous administration and hospitalization. The drug acts as a positive allosteric modulator of the γ-aminobutyric acid (GABAA) receptor, enhancing inhibitory neurotransmission in the brain—a mechanism believed to underlie its antidepressant effects. LPCN 1154 has demonstrated bioequivalence with IV brexanolone in pivotal studies and is currently in Phase 3 clinical trials designed to support global registration for PPD treatment[2][3][5][10].
- Brand names
- LPCN 1154LPCN1154LPCN-1154
- Other names
- oral brexanoloneoral allopregnanolone (bioidentical neuroactive steroid)
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on LPCN 1154.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPCN 1154.